Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. PRIM
6. META
7. SPY
8. DPZ
9. NAVN
10. NVDA

Go back to Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 4c

February 28, 2023 4:05 PM EST

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q4 EPS of ($0.66), $0.04 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $47 thousand versus the consensus estimate of $60.64 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

... More